Learn more about whether Glaukos Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

While glaucoma prevalence is growing, glaucoma specialists are in short supply, and accessibility to specialized centers is ...

Christine Funke, MD, glaucoma specialist at Barnet Dulaney Perkins Eye Center in Phoenix, Arizona, discusses how the ...

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that ...

MINT, a stent-free platform, helps treat adult patients undergoing glaucoma angle surgery. The system utilizes a unique ...

Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Background Normal tension glaucoma (NTG) is commonly treated with anti-glaucoma medications. Recently, selective laser trabeculoplasty (SLT) has been demonstrated to lower the intraocular pressure ...

Cataracts and glaucoma are two eye ailments frequently encountered by people in the later years of life due to aging. While both may affect vision, they differ greatly in terms of causes, symptoms, ...

The measure will likely upend the global medicine trade as most countries, the U.S. included, have no or few restrictions on finished drugs, partly because of an agreement struck by the World ...

Kennedy Jr. spoke with CBS News chief medical correspondent Dr. Jon LaPook about a range of topics, including measles, food additives and weight loss drugs. Here are some highlights from their ...

But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can’t make enough of their own ...